Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study
Transplant International · 2024
DOI: 10.3389/ti.2024.13641 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Marianna Maspero und 12 weiteren Autor:innen. Beteiligte Einrichtung: HPB Surgery, Hepatology and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Liver Transplantation, Bile Duct Neoplasms, Embolization, Therapeutic. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Liver transplantation (LT) is a potentially curative experimental treatment for unresectable intrahepatic cholangiocarcinoma (iCC). Pre-transplant downstaging may help defining tumor aggressiveness and drive patient selection. We report the preliminary results of LT for liver-limited unresectable iCC after sequential downstaging with systemic chemotherapy and radioembolization (SYS-TARE). In case of sustained disease stability after SYS-TARE, patients underwent surgical nodal sampling and, if negative, were listed for LT. In this study, 13 patients with unresectable iCC underwent downstaging with SYS-TARE. The median age was 70 years and 77% were female. All had single bulky lesions at diagnosis. After SYS-TARE, 9 (69%) dropped out: 3 due to progressive disease after TARE with no response to second-line, 4 due to extrahepatic disease development and 2 due to positive nodal disease at pre-listing abdominal exploration. The median OS after dropout was 11.5 months. Four (31%) were successfully listed and transplanted. At pathology, viable tumor ranged from 30% to less than 5%. All four patients are alive and disease-free at 73, 40, 12, and 8 months from LT. LT for unresectable iCC after downstaging with SYS-TARE appears to select suitable patients for LT, achieving optimal oncological outcomes in case of response to therapy and no lymphnodal spread.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- HPB Surgery, Hepatology and Liver Transplantation Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
- Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
- Interventional Radiology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
- Nuclear Medicine and Physics, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
- Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
- Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
Zitieren
APA
Maspero, M., Sposito, C., Bongini, M. A., Cascella, T., Flores, M., Maccauro, M., Chiesa, C., Niger, M., Pietrantonio, F., Leoncini, G., Bellia, V., Bhoori, S., & Mazzaferro, V. (2024). Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study. Transplant International. https://doi.org/10.3389/ti.2024.13641
Vancouver
Maspero M, Sposito C, Bongini MA, Cascella T, Flores M, Maccauro M, et al. Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study. Transplant International. 2024. doi:10.3389/ti.2024.13641
BibTeX
@article{Maspero2024,
author = {Maspero, Marianna and Sposito, Carlo and Bongini, Marco A and Cascella, Tommaso and Flores, Maria and Maccauro, Marco and Chiesa, Carlo and Niger, Monica and Pietrantonio, Filippo and Leoncini, Giuseppe and Bellia, Valentina and Bhoori, Sherrie and Mazzaferro, Vincenzo},
title = {Liver Transplantation for Intrahepatic Cholangiocarcinoma After Chemotherapy and Radioembolization: An Intention-To-Treat Study},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.13641}
}
EUVIMED